Post-Marketing Experience of Edaravone in Amyotrophic Lateral Sclerosis: A Clinical Perspective and Comparison With the Clinical Trials of the Drug

Juan Fernando Ortiz 1, Sawleha Arshi Khan 2, Amr Salem 3, Zayar Lin 4, Zafar Iqbal 5 6, Nusrat Jahan 4

Affiliations

10 June 2020

-

doi: 10.7759/cureus.10818

Abstract

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease that affects the upper and lower motor neurons. Currently, the only treatment for ALS is riluzole, which only has a limited effect on increasing survival from 3 to 6 months. New therapies are needed in the clinical setting for ALS. We aim to compare and contrast the clinical trials of edaravone and the post-marketing experience of the drug during this study. For the method, a search strategy was made using PubMed with the search terms "Amyotrophic lateral sclerosis" (MeSH) and "Edaravone" (MeSH). For inclusion criteria, we used full papers, studies involving humans, and studies published in the English language. We exclude meta-analyses, literature reviews, systematic reviews, studies involving animals, and studies not published in English. After close examination, 20 papers were used for the discussion in this review. The clinical trials showed efficacy in patients in reducing the revised ALS functional rating scale (ALSFRS-R) in patients with early ALS with selective criteria. We documented edaravone's post-marketing experience in six countries: Kuwait, South Korea, Argentina, United States, Israel, and Italy. During the study we analyzed, the forced vital capacity (FVC) and ALSFRS-R scored, together with edaravone's safety in the clinical trials and post-marketing experience. Edaravone seems to be more effective in Asia, where the ALSFRS-R scores and the FVC decline were similar to the clinical trial results in Japan. Studies in Europe did not find the drug clinically useful. At the same time, studies in United States and Argentina were mainly descriptive, so more information is needed to evaluate the drug's efficacy in that part of the world. The drug was well-tolerated in all studies. In conclusion, more studies need to be done worldwide to carry out and clarify the effectiveness of edaravone in the clinical setting.

Keywords: amyotrophic lateral sclerosis; edaravone.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Flowchart with the method applied and the results obtained during the review.

Figure 1. Flowchart with the method applied and the results obtained during the review.

Similar articles

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].

Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, Liu S, Zhang J, Apple S.PLoS One. 2022 Jun 14;17(6):e0258614. doi: 10.1371/journal.pone.0258614. eCollection 2022.PMID: 35700157 Free PMC article. Clinical Trial.

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study.

Park JM, Park D, Kim HJ, Park JS.BMC Neurol. 2022 Jul 14;22(1):260. doi: 10.1186/s12883-022-02788-x.PMID: 35836136 Free PMC article.

Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).

WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP.Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):40-48. doi: 10.1080/21678421.2017.1361441.PMID: 28872915 Clinical Trial.

Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis.

Sawada H.Expert Opin Pharmacother. 2017 May;18(7):735-738. doi: 10.1080/14656566.2017.1319937.PMID: 28406335 Review.

Edaravone and its clinical development for amyotrophic lateral sclerosis.

Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J.Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):5-10. doi: 10.1080/21678421.2017.1353101.PMID: 28872907 Review.

Cited by

Amyotrophic Lateral Sclerosis Pathoetiology and Pathophysiology: Roles of Astrocytes, Gut Microbiome, and Muscle Interactions via the Mitochondrial Melatonergic Pathway, with Disruption by Glyphosate-Based Herbicides.

Anderson G.Int J Mol Sci. 2022 Dec 29;24(1):587. doi: 10.3390/ijms24010587.PMID: 36614029 Free PMC article. Review.

Use of Riluzole for the Treatment of Hereditary Ataxias: A Systematic Review.

Ayala IN, Aziz S, Argudo JM, Yepez M, Camacho M, Ojeda D, Aguirre AS, Oña S, Andrade AF, Vasudhar A, Moncayo JA, Hassen G, Ortiz JF, Tambo W.Brain Sci. 2022 Aug 5;12(8):1040. doi: 10.3390/brainsci12081040.PMID: 36009103 Free PMC article. Review.

Ethnical Disparities in Response to Edaravone in Patients With Amyotrophic Lateral Sclerosis.

Jayasinghe M, Jena R, Singhal M, Jain S, Karnakoti S, Silva MS, Kayani AMA.Cureus. 2022 Jun 15;14(6):e25960. doi: 10.7759/cureus.25960. eCollection 2022 Jun.PMID: 35855239 Free PMC article. Review.

Analysis of the US Safety Data for Edaravone (Radicava®) From the Third Year After Launch.

Genge A, Brooks BR, Oskarsson B, Kalin A, Ji M, Apple S, Bower L.Drugs R D. 2022 Sep;22(3):205-211. doi: 10.1007/s40268-022-00391-6. Epub 2022 Jun 20.PMID: 35723868 Free PMC article.

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686].

Brooks BR, Heiman-Patterson T, Wiedau-Pazos M, Liu S, Zhang J, Apple S.PLoS One. 2022 Jun 14;17(6):e0258614. doi: 10.1371/journal.pone.0258614. eCollection 2022.PMID: 35700157 Free PMC article. Clinical Trial.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. The epidemiology of amyotrophic lateral sclerosis. Talbott EO, Malek AM, Lacomis D. Handb Clin Neurol. 2016;138:225–238. - PubMed
  2.  
    1. Amyotrophic lateral sclerosis: an update for 2018. Oskarsson B, Gendron TF, Staff NP. Mayo Clin Proc. 2018;93:1617–1628. - PubMed
  3.  
    1. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Miller RG, Mitchell JD, Lyon M, Moore DH. Cochrane Database Syst Rev. 2002:0. - PubMed
  4.  
    1. Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis. Dorst J, Ludolph AC, Huebers A. Ther Adv Neurol Disord. 2017;11:1–16.
  5.  
    1. Edaravone for amyotrophic lateral sclerosis: more evidence for long-term benefit. Distad BJ, Weiss MD. Muscle Nerve. 2020;61:129–130. - PubMed
  6.  
    1. Edaravone: a new treatment for ALS on the horizon? Hardiman O, van den Berg LH. Lancet Neurol. 2017;16:490–491. - PubMed
  7.  
    1. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Abe K, Itoyama Y, Sobue G, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:610–617. - PMC - PubMed
  8.  
    1. Post-hoc analysis of randomized, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Takei K, Takahashi F, Liu S, Tsuda K, Palumbo J. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:49–54. - PubMed
  9.  
    1. Update on amyotrophic lateral sclerosis genetics. Brenner D, Weishaupt JH. Curr Opin Neurol. 2019;32:735–739. - PubMed
  10.  
    1. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Redox Rep. 2016;21:104–112. - PMC - PubMed
  11.  
    1. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study) Yoshino H, Kimura A. Amyotroph Lateral Scler. 2006;7:241–245. - PubMed
  12.  
    1. Safety and efficacy of edaravone in well-defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Writing Group; Edaravone (MCI-186) ALS 19 Study Group. Lancet Neurol. 2017;16:505–512. - PubMed
  13.  
    1. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Takahashi F, Takei K, Tsuda K, Palumbo J. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:32–39. - PubMed
  14.  
    1. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation) The Writing Group on Behalf of the Edaravone (MCI-186) ALS 18 Study Group. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:40–48. - PubMed
  15.  
    1. Exploratory double-blind, parallel-group, placebo-controlled extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Writing Group on Behalf of the Edaravone (MCI-186) ALS 17 Study Group. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:20–31. - PubMed
  16.  
    1. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Takei K, Tsuda K, Takahashi F, Palumbo J. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:64–70. - PubMed
  17.  
    1. Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of study 19 (MCI186-19) Shefner J, Heiman-Patterson T, Pioro EP, et al. Muscle Nerve. 2020;61:218–221. - PMC - PubMed
  18.  
    1. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Edaravone (MCI-186) ALS 16 Study Group. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:11–19. - PubMed
  19.  
    1. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. Jackson C, Heiman-Patterson T, Kittrell P, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:605–610. - PubMed
  20.  
    1. Logistics and safety of edaravone treatment for amyotrophic lateral sclerosis: experience in Argentina [IN PRESS] Quarracino C, Bendersky M, Rey R. Acta Neurol Belg. 2020 - PubMed
  21.  
    1. Effect of edaravone therapy in Korean amyotrophic lateral sclerosis (ALS) patients. Park JM, Kim SY, Park D, Park JS. Neurol Sci. 2020;41:119–123. - PMC - PubMed
  22.  
    1. Evaluation of clinical outcome and safety profile of edaravone in treatment of amyotrophic lateral sclerosis: a 72-week single-center experience [IN PRESS] Ismail II, Massoud F, Kamel WA, Al-Hashel JY. Acta Neurol Belg. 2020 - PubMed
  23.  
    1. Early post-marketing experience with edaravone in an unselected group of patients with ALS. Abraham A, Nefussy B, Fainmesser Y, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:260–263. - PubMed
  24.  
    1. Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. Fortuna A, Gizzi M, Bello L, et al. J Neurol Sci. 2019;404:47–51. - PubMed
  25.  
    1. The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis [IN PRESS] Lunetta C, Moglia C, Lizio A, et al. J Neurol. 2020 - PubMed
  26.  
    1. Clinical significance in the change of decline in ALSFRS-R. Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Amyotroph Lateral Scler. 2010;11:178–180. - PubMed

Page Navigation